78
Participants
Start Date
June 17, 2019
Primary Completion Date
March 15, 2021
Study Completion Date
September 30, 2023
TOL-3021
TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
TOL-3021 Placebo
TOL-3021 Placebo
Naomi Berrie Diabetes Center, Columbia University, New York
SUNY Upstate Medical University, Syracuse
MedStar Health Research Institute, Hyattsville
MedStar Health Research Institute, Baltimore
University of Virginia, Charlottesville
University of North Carolina Diabetes Care Center, Chapel Hill
Mountain Diabetes and Endocrine Center, Asheville
Emory University, Atlanta
Baptist Health Research Institute, Jacksonville
University of Florida, Gainesville
University of Miami Diabetes Research Institute, Miami
University of South Florida Diabetes Center, Tampa
University of Iowa, Iowa City
Children's Mercy Hospital, Kansas City
Diabetes and Glandular Disease Clinic, P.A., San Antonio
Barbara Davis Center - University of Colorado Denver, Denver
Rocky Mountain Clinical Research, Idaho Falls
Altman Clinical and Translational Research Institute UCSD, San Diego
University of California San Francisco, San Francisco
Stanford University, Stanford
Mills-Peninsula Medical Center, San Mateo
Yale University, New Haven
Joslin Diabetes Center- Adult & Pediatric, Boston
Tolerion, Inc.
INDUSTRY